Advertisement
Advertisement
BIO.B
Bio-Rad Laboratories, Inc. Class B
276.86
USDSponsored
-1.39
-0.50%
Apr 02, 15:59 UTC -4
Closed
After-Market
276.86
0.00
0.00%
BIO.B Earnings Reports
Positive Surprise Ratio
BIO.B beat 29 of 41 last estimates.
71%
Next Report
Date of Next Report
Apr 30, 2026
Estimate for Q1 26 (Revenue/ EPS)
$590.82M
/$1.82
Implied change from Q4 25 (Revenue/ EPS)
-14.77%
/-27.20%
Implied change from Q1 25 (Revenue/ EPS)
+0.93%
/-28.35%
Bio-Rad Laboratories, Inc. Class B earnings per share and revenue
On Feb 12, 2026, BIO.B reported earnings of 2.50 USD per share (EPS) for Q4 25, missing the estimate of 2.72 USD, resulting in a -7.97% surprise. Revenue reached 693.20 million, compared to an expected 695.65 million, with a -0.35% difference.
Looking ahead to Q1 26, 6 analysts forecast an EPS of 1.82 USD, with revenue projected to reach 590.82 million USD, implying an decrease of -27.20% EPS, and decrease of -14.77% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Pharvaris N.V. Ordinary Shares
Report Date
Apr 02, 2026 For Q4 25
Estimate
-$0.63
Actual
-$0.72
Surprise
-13.69%
Palvella Therapeutics, Inc. Common Stock
Report Date
Mar 31, 2026 For Q4 25
Estimate
-$0.92
Actual
-$1.07
Surprise
-15.20%
Forte Biosciences, Inc. Common Stock
Report Date
Mar 31, 2026 For Q4 25
Estimate
-$1.23
Actual
-$1.39
Surprise
-12.31%
Innate Pharma S.A. ADS
Report Date
Apr 01, 2026 For Q1 26
Estimate
-$0.12
Actual
-$0.55
Surprise
-353.80%
Femasys Inc. Common Stock
Report Date
Mar 31, 2026 For Q4 25
Estimate
-$0.08
Actual
-$0.01
Surprise
+88.80%
Tevogen Bio Holdings Inc. Common Stock
Report Date
Mar 31, 2026 For Q4 25
Estimate
-$2.04
Actual
-$1.45
Surprise
+28.92%
Kairos Pharma, Ltd.
Report Date
Mar 31, 2026 For Q4 25
Estimate
-$0.05
Actual
-$0.07
Surprise
-28.68%
BioAtla, Inc. Common Stock
Report Date
Mar 31, 2026 For Q4 25
Estimate
-$0.24
Actual
-$0.16
Surprise
+34.64%
Imunon, Inc. Common Stock
Report Date
Mar 31, 2026 For Q4 25
Estimate
-$1.19
Actual
-$2.02
Surprise
-68.69%
Cyclerion Therapeutics, Inc. Common Stock
Report Date
Mar 31, 2026 For Q4 25
Estimate
-$0.38
Actual
-$0.21
Surprise
+45.82%
FAQ
What were Bio-Rad Laboratories, Inc. Class B's earnings and revenue for the latest quarter Q4 2025?
For Q4 2025, Bio-Rad Laboratories, Inc. Class B reported EPS of $2.50, missing estimates by -7.97%, and revenue of $693.20M, -0.35% below expectations.
How did the market react to Bio-Rad Laboratories, Inc. Class B's Q4 2025 earnings?
The stock price moved -- --, changed from -- before the earnings release to -- the day after.
When is Bio-Rad Laboratories, Inc. Class B expected to report next?
The next earning report is scheduled for Apr 30, 2026.
What are the forecasts for Bio-Rad Laboratories, Inc. Class B's next earnings report?
Based on 6
analysts, Bio-Rad Laboratories, Inc. Class B is expected to report EPS of $1.82 and revenue of $590.82M for Q1 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement